DZ Bank analyst Elmar Kraus downgraded Gilead Sciences to Hold from Buy with a $90 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Arcellx Soars on Key Deal with Gilead’s Kite
- ImmunoGen Joins hands with Gilead on AML Therapy
- Daiichi data competitive to Trodelvy, but 2 years behind Gilead, says Piper
- Gilead’s Kite Pharma, Daiichi Sankyo announce partnership revision
- Kite, Daiichi Sankyo announces changes to Yescarta licensing deal in Japan